Patents Assigned to Excaliard Pharamaceuticals, Inc.
  • Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
    Patent number: 9173894
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: November 3, 2015
    Assignee: Excaliard Pharamaceuticals, Inc.
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell